A double-blind study comparing paroxetine
and maprotiline in depressed outpatients
by
Szegedi A, Wetzel H, Angersbach D, Dunbar GC,
Schwarze H, Philipp M, Benkert O
Department of Psychiatry,
University of Mainz, Germany.
Pharmacopsychiatry 1997 May; 30(3):97-105

ABSTRACT

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comprised rating of the HAMD-17, MADRS, BRMS, RDS, HAMA, CAS, and CGI scales and registration of adverse events by non-leading questions. An intention-to-treat and a completer analysis were performed. Response was defined as a HAMD-17 reduction of > or = 50% or a HAMD-17 score of < or = 9 at the end of the study or at dropout. The treatment groups were comparable according to demographic data. Overall evaluation indicated equieffective and good antidepressant and anxiety-reducing properties for paroxetine and maprotiline. No persistent significant differences between treatment groups were observed on any assessment instrument. There was no difference in the frequency of observed side-effects, but side-effect profiles were markedly different, as maprotiline patients had more anticholinergic and paroxetine patients more SSRI-typical side-effects.

Paroxetine
Reboxetine
Amineptine
Dumb drugs
Desipramine
TCAs v SSRIs
Norepinephrine
Paroxetine: review
Paroxetine: update
Stopping paroxetine
Antidepressant toxicity
Paroxetine in psychiatry
Maprotiline versus mianserin
Maprotiline versus amitriptiline
Maprotiline versus fluvoxamine
Maprotiline versus moclobemide
Paroxetine v escitalopram (Lexapro)
Psychopharmacology of mood and anxiety disorders

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family